Pacira BioSciences (PCRX)
(Delayed Data from NSDQ)
$20.03 USD
+0.05 (0.25%)
Updated Jul 26, 2024 04:00 PM ET
After-Market: $20.04 +0.01 (0.05%) 7:58 PM ET
3-Hold of 5 3
A Value B Growth F Momentum A VGM
Brokerage Reports
0 items in cart
Pacira BioSciences, Inc. [PCRX]
Reports for Purchase
Showing records 61 - 80 ( 722 total )
Company: Pacira BioSciences, Inc.
Industry: Medical - Drugs
2023 Outlook - New Commercial Launches, Clinical Catalysts & M&A Driving Value
Provider: Wedbush Securities Inc.
Analyst: Research Department
Company: Pacira BioSciences, Inc.
Industry: Medical - Drugs
Company: Pacira BioSciences, Inc.
Industry: Medical - Drugs
No Pain is Pacira''s Gain; NOPAIN Act Set to Boost EXPAREL
Provider: Wedbush Securities Inc.
Analyst: MOUSSATOS L
Company: Pacira BioSciences, Inc.
Industry: Medical - Drugs
Perspectives from Virtual Road: Looking to Volume Growth in 2023
Provider: Wedbush Securities Inc.
Analyst: MOUSSATOS L
Company: Pacira BioSciences, Inc.
Industry: Medical - Drugs
Perspectives from Virtual Road: Looking to Volume Growth in 2023
Provider: Wedbush Securities Inc.
Analyst: MOUSSATOS L
Company: Pacira BioSciences, Inc.
Industry: Medical - Drugs
Company: Pacira BioSciences, Inc.
Industry: Medical - Drugs
Provider: Zacks Investment Research
Analyst: Research Department
Company: Pacira BioSciences, Inc.
Industry: Medical - Drugs
November Preliminary Sales; Additional EXPAREL Growth Potential in 2023
Provider: Wedbush Securities Inc.
Analyst: MOUSSATOS L
Company: Pacira BioSciences, Inc.
Industry: Medical - Drugs
Provider: Zacks Investment Research
Analyst: Research Department
Company: Pacira BioSciences, Inc.
Industry: Medical - Drugs
Company: Pacira BioSciences, Inc.
Industry: Medical - Drugs
Company: Pacira BioSciences, Inc.
Industry: Medical - Drugs
Provider: Zacks Investment Research
Analyst: Research Department
Company: Pacira BioSciences, Inc.
Industry: Medical - Drugs
Company: Pacira BioSciences, Inc.
Industry: Medical - Drugs
Q3: Uncertainty Building in Elective Surgery Market; Pipeline Progress
Provider: Wedbush Securities Inc.
Analyst: MOUSSATOS L
Company: Pacira BioSciences, Inc.
Industry: Medical - Drugs
3Q22: Surprising Manufacturing Hiccups Still; Apparently Resolved; Growth Prospects Intact; PT Tweaked Down to $76
Provider: H.C. Wainwright & Co., Inc.
Analyst: LIVNAT O
Company: Pacira BioSciences, Inc.
Industry: Medical - Drugs
Company: Pacira BioSciences, Inc.
Industry: Medical - Drugs
Provider: Zacks Investment Research
Analyst: Research Department
Company: Pacira BioSciences, Inc.
Industry: Medical - Drugs
3Q Soft Sales Pre-announce Not Surprising Given Macro Headwind; Still See Sequential Earnings Improvement; Reit. Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: LIVNAT O
Company: Pacira BioSciences, Inc.
Industry: Medical - Drugs
Company: Pacira BioSciences, Inc.
Industry: Medical - Drugs
Provider: Zacks Investment Research
Analyst: Research Department